A Burden of Disease Model for Assessing the Economic and Outcomes Impact of Diseases Associated with HPV Infection

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F24%3A00376549" target="_blank" >RIV/68407700:21460/24:00376549 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1007/978-3-031-62520-6_11" target="_blank" >https://doi.org/10.1007/978-3-031-62520-6_11</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-031-62520-6_11" target="_blank" >10.1007/978-3-031-62520-6_11</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A Burden of Disease Model for Assessing the Economic and Outcomes Impact of Diseases Associated with HPV Infection

Popis výsledku v původním jazyce

Human papillomavirus infection can be associated with a different spectrum of diseases, which in many cases are not manifested until several years after the first infection. The economic and clinical impacts of these infections must be estimated over a lifetime. The aim of this study is to assess the economic and health burden of human papillomavirus-associated diseases in the Czech Republic. A Markov model was created to estimate lifetime direct and indirect costs and benefits in the form of quality adjusted life years, years of life lost, and the number of deaths from cancers associated with Human papillomavirus infection. The model compared the scenario with vaccination of the female population and the male population with the scenario without vaccination. Simulation results suggest that vaccination, although associated with high initial costs, is an intervention that has lower lifetime costs and higher benefits.

Název v anglickém jazyce

A Burden of Disease Model for Assessing the Economic and Outcomes Impact of Diseases Associated with HPV Infection

Popis výsledku anglicky

Human papillomavirus infection can be associated with a different spectrum of diseases, which in many cases are not manifested until several years after the first infection. The economic and clinical impacts of these infections must be estimated over a lifetime. The aim of this study is to assess the economic and health burden of human papillomavirus-associated diseases in the Czech Republic. A Markov model was created to estimate lifetime direct and indirect costs and benefits in the form of quality adjusted life years, years of life lost, and the number of deaths from cancers associated with Human papillomavirus infection. The model compared the scenario with vaccination of the female population and the male population with the scenario without vaccination. Simulation results suggest that vaccination, although associated with high initial costs, is an intervention that has lower lifetime costs and higher benefits.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

30302 - Epidemiology

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

Advances in Digital Health and Medical Bioengineering, Proceedings of the 11th International Conference on E-Health and Bioengineering, EHB-2023, November 9–10, 2023, Bucharest, Romania – Volume 2: Health Technology Assessment, Biomedical Signal Processing, Medicine and Informatics

ISBN

978-3-031-62519-0

ISSN

1680-0737

e-ISSN

1433-9277

Počet stran výsledku

9

Strana od-do

85-93

Název nakladatele

Springer Nature Switzerland AG

Místo vydání

Basel

Místo konání akce

Bucuresti

Datum konání akce

9. 11. 2023

Typ akce podle státní příslušnosti

WRD - Celosvětová akce

Kód UT WoS článku

001326809000011